Get the Stockscreener App
3.64
0.00%
0.00
After Hours:
3.33
-0.31
-8.52%
Newcelx Ltd stock is traded at $3.64, with a volume of 31,208.
It is up +0.00% in the last 24 hours and down -22.55% over the past month.
NewcelX Ltd is a biotechnology company developing transformative cell-based and small-molecule therapies for neurodegenerative and metabolic diseases. The company's integrated platform combines advanced stem-cell technologies and neuroscience expertise to deliver scalable, regenerative treatments targeting conditions such as Amyotrophic Lateral Sclerosis (ALS) and Type 1 Diabetes. It has research and development operations in Ness Ziona, Israel.
See More
Previous Close:
$3.64
Open:
$3.76
24h Volume:
31,208
Relative Volume:
1.09
Market Cap:
$16.59M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-9.23%
1M Performance:
-22.55%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$3.49
$3.91
1-Week Range:
$3.30
$4.0665
52-Week Range:
$3.062
$6.48
Newcelx Ltd Stock (NCEL) Company Profile
Compare NCEL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NCEL
Newcelx Ltd
|
3.64 | 16.46M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.48 | 116.04B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
718.36 | 75.97B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
458.12 | 61.48B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
901.17 | 56.40B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
204.00 | 43.73B | 447.02M | -1.18B | -906.14M | -6.1812 |
Newcelx Ltd Stock (NCEL) Latest News
NewcelX Ltd. (NCEL) -8.5% in After-hours: Decline Amid Routine Trading Conditions - Stocks Telegraph
NLSP SEC FilingsNls Pharmaceutics Ltd 10-K, 10-Q, 8-K Forms - Stock Titan
NewcelX Announces Scientific Leadership with the Head of Division of Medical Neurosciences at the Department of Neurology at Hadassah, Prof. Tamir Ben-Hur on Its Scientific Advisory Board (PR Newswire) - Aktiellt
NewcelX Ltd.Ordinary Shares (NQ: NCEL - Markets Financial Content
NewCelX Appoints EY as New Auditor Following Merger - MSN
[6-K] NLS Pharmaceutics Ltd. Current Report (Foreign Issuer) | NLSP SEC FilingForm 6-K - Stock Titan
NewcelX appoints ALS specialist to scientific advisory board By Investing.com - Investing.com Nigeria
NewcelX appoints ALS specialist to scientific advisory board - Investing.com
NewcelX Strengthens Scientific Advisory Board with Appointment of Jeremy Shefner, MD, PhD, Chief Medical Officer at the Barrow Neurological Institute - Finviz
NewcelX Appoints Renowned Neurologist to Strengthen Scientific Advisory Board - TipRanks
Price to sales ratio of NewcelX Ltd. – NASDAQ:NCEL - TradingView
Press Release: NewcelX Announces Scientific Leadership With the Head of Division of Medical Neurosciences at the Department of Neurology at Hadassah, Prof. Tamir Ben-Hur on Its Scientific Advisory Board - 富途牛牛
NewcelX Ltd. (NCEL) - Zacks Investment Research
NLS Pharmaceutics to execute 1-for-10 reverse share split - MSN
NewcelX Ltd. (NCEL) company profile and facts - Yahoo Finance UK
NewcelX Announces New CFO Appointment Following Merger - MSN
NewcelX Ltd. (NCEL) interactive stock chart - Yahoo Finance UK
NewcelX Ltd. (NCEL) Stock Forum & Discussion - Yahoo! Finance Canada
NewcelX Ltd (NCEL) Stock Forecast, Price Targets and Analysts Predictions - GuruFocus
NewcelX Ltd (NCEL) Stock Earnings Transcripts - GuruFocus
NewcelX appoints Omri Hagai as chief financial officer, effective December 10 By Investing.com - Investing.com Australia
NewcelX appoints Omri Hagai as chief financial officer, effective December 10 - Investing.com India
Neurology expert Prof. Ben-Hur joins NewcelX scientific board By Investing.com - Investing.com Nigeria
NewcelX Ltd. Revenue Breakdown – NASDAQ:NCEL - TradingView
NLS Pharmaceutics Announces Reverse Share Split and Name Change Amid Merger - MSN
NewcelX Ltd. (NCEL) analyst ratings, estimates and forecasts - Yahoo Finance Australia
NewcelX Ltd. (NCEL) Income Statement - Yahoo! Finance Canada
NewcelX Ltd. (NCEL) valuation measures and financial statistics - Yahoo Finance Australia
NCEL Interactive Stock Chart | NewcelX Ltd. Stock - Yahoo Finance
NewcelX Announces Scientific Leadership with the Head of Division of Medical Neurosciences at the Department of Neurology at Hadassah, Prof. Tamir Ben-Hur on Its Scientific Advisory Board - WV News
Neurology expert Prof. Ben-Hur joins NewcelX scientific board - Investing.com
NewcelX Ltd. (NCEL) Stock Major Holders - Yahoo! Finance Canada
NewcelX Ltd. (NCEL) Latest Stock News & Headlines - Yahoo! Finance Canada
NCEL Financial Statements & ChartsNewcelx Ltd MacroTrends - CMLviz
NCEL Pivot Points, Technical Analysis and Moving AveragesNewcelx Ltd Technicals - CMLviz
NewcelX outlines clinical development roadmap for neurodegenerative therapies By Investing.com - Investing.com Nigeria
NewcelX outlines clinical development roadmap for neurodegenerative therapies - Investing.com India
NewcelX Ltd. (NCEL) stock price, news, quote and history - Yahoo Finance UK
NCEL News Today | Why did NLS Pharmaceutics stock go up today? - MarketBeat
NewcelX Ltd. (NCEL) Stock Price, News, Quote & History - Yahoo! Finance Canada
NewcelX Ltd. (KDST.TA) Stock Price, News, Quote & History - Yahoo! Finance Canada
NLS Pharmaceutics (NCEL) Stock Price, News & Analysis - MarketBeat
NewcelX Ltd. (NCEL) Options Chain - Yahoo! Finance Canada
NewcelX Ltd. (NCEL) Valuation Measures & Financial Statistics - Yahoo! Finance Canada
NLS Pharmaceutics Ltd. and Kadimastem Ltd. Announce the Initial Closing of $500,000 of the Previously Announced $1 Million Fundraising by NLS Following its Extraordinary General Meeting at a Share Price of $3.10, Representing 48% Above the Market S - MarketScreener
NewcelX Unveils Strategic Initiatives and Clinical Advancements - TipRanks
NewceIX CEO issues letter to shareholders - MarketScreener
Newcelx Ltd Stock (NCEL) Financials Data
There is no financial data for Newcelx Ltd (NCEL). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
1.44%
0.91%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):